6 May 2026
Sun Pharma’s USD 11.75 billion acquisition of Organon marks its biggest deal and elevates it into the top 25 global pharma companies.
Organon, with strong roots in women’s health and notable contributions like the research lineage behind Keytruda and Sun’s own Ilumya, brings valuable brands but a heavy debt burden.
Organon was spun off from Merck with a massive USD 9.5 billion debt, which later reduced to USD 8.6 billion. It depressed its valuation and made the acquisition risky.
Sun had acquired Ilumya from Merck for USD 80 million while the drug awaited FDA approval. This became its flagship product for treating moderate‑to‑severe plaque psoriasis. Analysts had called it risky and wrong as Sun had entered a market dominated by Novartis, J&J, and Elli Lilly with a non-approved drug.
Sun expects USD 350 million in synergies within 2–3 years. Shanghvi has a long history of turning around distressed acquisitions, such as TDPL, Caraco, Taro, and Ranbaxy.
The Organon deal offers scale but demands exceptional execution in a highly competitive landscape.
Check out my new book, THE FLAMES TURN WHITE – THE BLACK FLAMES series book II.
A gripping, high-stakes mystery.